Patents by Inventor John Desjarlais

John Desjarlais has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Heterodimeric antibodies that bind CD3 and tumor antigens
    Patent number: 11945880
    Abstract: The present invention is directed to novel heterodimeric antibodies.
    Type: Grant
    Filed: December 3, 2021
    Date of Patent: April 2, 2024
    Assignee: Xencor, Inc.
    Inventors: Matthew J. Bernett, Gregory Moore, John Desjarlais, Seung Chu, Rumana Rashid, Umesh Muchhal, Sung-Hyung Lee
  • HETERODIMERIC PROTEINS
    Publication number: 20240092871
    Abstract: In one aspect, the present invention provides heterodimeric antibodies comprising a first monomer comprising a first heavy chain constant domain comprising a first variant Fc domain and a first antigen binding domain and a second monomer comprising a second heavy chain constant domain comprising a second variant Fc domain and a second antigen binding domain. In an additional aspect the heterodimeric antibody comprises a first monomer comprising a heavy chain comprising a first Fc domain and a single chain Fv region (scFv) that binds a first antigen, wherein the scFv comprises a charged scFv linker. The heterodimeric antibody further comprises a second monomer comprising a first heavy chain comprising a second Fc domain and a first variable heavy chain and a first light chain.
    Type: Application
    Filed: September 7, 2023
    Publication date: March 21, 2024
    Inventors: Gregory Moore, Matthew Bernett, Rumana Rashid, John Desjarlais
  • PD-1 targeted IL-15/IL-15R? Fc fusion proteins with improved properties
    Patent number: 11932675
    Abstract: The present invention relates to fusion proteins comprising variant IL-15 proteins, fusion proteins comprising variant anti-PD-1 antigen binding domains, and fusion proteins comprising variant IL-15 proteins and variant anti-PD-1 antigen binding domains. The present invention also relates to nucleic acid molecules, expression vectors, host cells and methods for making such fusion proteins and the use of such fusion proteins in the treatment of cancer.
    Type: Grant
    Filed: October 9, 2020
    Date of Patent: March 19, 2024
    Assignees: GENENTECH, INC., XENCOR, INC.
    Inventors: John Desjarlais, Matthew Bernett, Michael Hedvat, Rajat Varma, Suzanne Schubbert, Christine Bonzon, Rumana Rashid, Juan Diaz, Patrick Holder, Christine Huang
  • BISPECIFIC IMMUNOMODULATORY ANTIBODIES THAT BIND COSTIMULATORY AND CHECKPOINT RECEPTORS
    Publication number: 20240026002
    Abstract: The present invention is directed to bispecific, heterodimeric immunomodulatory antibodies.
    Type: Application
    Filed: August 18, 2023
    Publication date: January 25, 2024
    Inventors: Matthew J. Bernett, Gregory Moore, John Desjarlais, Michael Hedvat, Christine Bonzon
  • OPTIMIZED Fc VARIANTS
    Publication number: 20240026023
    Abstract: The present invention relates to Fc variants having decreased affinity for Fc?RIIb, methods for their generation, Fc polypeptides comprising optimized Fc variants, and methods for using optimized Fc variants.
    Type: Application
    Filed: August 25, 2023
    Publication date: January 25, 2024
    Inventors: Gregory Lazar, Wei Dang, John Desjarlais, Sher Karki, Omid Vafa, Robert Hayes, Jost Vielmetter
  • Heterodimeric antibodies that bind CD3 and tumor antigens
    Patent number: 11859011
    Abstract: The present invention is directed to novel heterodimeric antibodies.
    Type: Grant
    Filed: October 18, 2021
    Date of Patent: January 2, 2024
    Assignee: Xencor, Inc.
    Inventors: Matthew J. Bernett, Gregory Moore, John Desjarlais, Seung Chu, Rumana Rashid, Umesh Muchhal, Sung-Hyung Lee
  • OPTIMIZED ANTIBODY VARIABLE REGIONS
    Publication number: 20230399401
    Abstract: The present invention is directed to optimized anti-CD3 variable sequences for use in a variety of bispecific formats, including those that utilize scFv components. The invention further relates to nucleic acids encoding for the polypeptide, to vectors comprising the same and to host cells comprising the vector. In another aspect, the invention provides for a pharmaceutical composition comprising the mentioned polypeptide and medical uses of the polypeptide.
    Type: Application
    Filed: June 9, 2023
    Publication date: December 14, 2023
    Inventors: Gregory Moore, Matthew Bernett, Rumana Rashid, John Desjarlais
  • Bispecific antibodies that bind to CD38 and CD3
    Patent number: 11840579
    Abstract: The invention provides novel heterodimeric proteins including heterodimeric antibodies.
    Type: Grant
    Filed: October 30, 2020
    Date of Patent: December 12, 2023
    Assignee: Xencor, Inc.
    Inventors: Matthew Bernett, Seung Chu, Gregory Moore, John Desjarlais
  • Optimized Fc variants
    Patent number: 11820830
    Abstract: The present invention relates to Fc variants having decreased affinity for Fc?RIIb, methods for their generation, Fc polypeptides comprising optimized Fc variants, and methods for using optimized Fc variants.
    Type: Grant
    Filed: July 29, 2020
    Date of Patent: November 21, 2023
    Assignee: Xencor, Inc.
    Inventors: Gregory Lazar, Wei Dang, John Desjarlais, Sher Karki, Omid Vafa, Robert Hayes, Jost Vielmetter
  • HETERODIMERIC ANTIBODIES THAT BIND CD3 AND TUMOR ANTIGENS
    Publication number: 20230365717
    Abstract: The present invention is directed to novel heterodimeric antibodies.
    Type: Application
    Filed: April 27, 2023
    Publication date: November 16, 2023
    Inventors: Matthew Bernett, Gregory Moore, John Desjarlais, Seung Chu, Rumana Rashid, Umesh Muchhal, Sung-Hyung Lee
  • Heterodimeric proteins
    Patent number: 11814423
    Abstract: In one aspect, the present invention provides heterodimeric antibodies comprising a first monomer comprising a first heavy chain constant domain comprising a first variant Fc domain and a first antigen binding domain and a second monomer comprising a second heavy chain constant domain comprising a second variant Fc domain and a second antigen binding domain. In an additional aspect the heterodimeric antibody comprises a first monomer comprising a heavy chain comprising a first Fc domain and a single chain Fv region (scFv) that binds a first antigen, wherein the scFv comprises a charged scFv linker. The heterodimeric antibody further comprises a second monomer comprising a first heavy chain comprising a second Fc domain and a first variable heavy chain and a first light chain.
    Type: Grant
    Filed: November 2, 2020
    Date of Patent: November 14, 2023
    Assignee: Xencor, Inc.
    Inventors: Gregory Moore, Matthew Bernett, Rumana Rashid, John Desjarlais
  • TIM-3 TARGETED HETERODIMERIC FUSION PROTEINS CONTAINING IL-15/IL-15RA Fc-FUSION PROTEINS AND TIM-3 ANTIGEN BINDING DOMAINS
    Publication number: 20230331813
    Abstract: The present invention is directed to novel targeted heterodimeric fusion proteins comprising an IL-15/IL-15R? Fc-fusion protein and a TIM-3 antibody fragment-Fc fusion protein.
    Type: Application
    Filed: October 13, 2022
    Publication date: October 19, 2023
    Inventors: Matthew J. Bernett, John Desjarlais, Rumana Rashid, Rajat Varma, Christine Bonzon
  • NOVEL HETERODIMERIC PROTEINS
    Publication number: 20230279154
    Abstract: The invention provides novel heterodimeric proteins including heterodimeric antibodies.
    Type: Application
    Filed: March 10, 2023
    Publication date: September 7, 2023
    Inventors: Gregory Moore, Matthew Bernett, Rumana Rashid, John Desjarlais
  • LAG-3 TARGETED HETERODIMERIC FUSION PROTEINS CONTAINING IL-15/IL-15RA Fc-FUSION PROTEINS AND LAG-3 ANTIGEN BINDING DOMAINS
    Publication number: 20230279071
    Abstract: The present invention is directed to novel targeted heterodimeric fusion proteins comprising an IL-15/IL-15R? Fc-fusion protein and a LAG-3 antibody fragment-Fc fusion protein.
    Type: Application
    Filed: April 28, 2023
    Publication date: September 7, 2023
    Inventors: Matthew J. Bernett, John Desjarlais, Rumana Rashid, Rajat Varma, Christine Bonzon
  • Optimized antibody variable regions
    Patent number: 11718667
    Abstract: The present invention is directed to optimized anti-CD3 variable sequences for use in a variety of bispecific formats, including those that utilize scFv components. The invention further relates to nucleic acids encoding for the polypeptide, to vectors comprising the same and to host cells comprising the vector. In another aspect, the invention provides for a pharmaceutical composition comprising the mentioned polypeptide and medical uses of the polypeptide.
    Type: Grant
    Filed: June 4, 2021
    Date of Patent: August 8, 2023
    Assignee: Xencor, Inc.
    Inventors: Gregory Moore, Matthew Bernett, Rumana Rashid, John Desjarlais
  • BISPECIFIC HETERODIMERIC FUSION PROTEINS CONTAINING IL-15 - IL-15Ralpha Fc-FUSION PROTEINS AND IMMUNE CHECKPOINT ANTIBODY FRAGMENTS
    Publication number: 20230220081
    Abstract: The present invention is directed to novel bispecific heterodimeric Fc fusion proteins comprising an IL-15/IL-15R? Fc-fusion protein and a PD-1 antibody fragment-Fc fusion protein.
    Type: Application
    Filed: December 13, 2022
    Publication date: July 13, 2023
    Inventors: Matthew Bernett, Rumana Rashid, John Desjarlais, Rajat Varma, Christine Bonzon
  • Heterodimeric antibodies that bind CD3 and tumor antigens
    Patent number: 11673972
    Abstract: The present invention is directed to novel heterodimeric antibodies.
    Type: Grant
    Filed: December 16, 2020
    Date of Patent: June 13, 2023
    Assignee: Xencor, Inc.
    Inventors: Matthew J. Bernett, Gregory Moore, John Desjarlais, Seung Chu, Rumana Rashid, Umesh Muchhal, Sung-Hyung Lee
  • BISPECIFIC ANTIBODIES THAT BIND TO B7H3 AND NKG2D
    Publication number: 20230151095
    Abstract: Provided herein are bispecific antibodies that bind to B7H3 and NKG2D (e.g., antibodies having Fab-scFv-Fc, Fab2-scFv-Fc, mAb-scFv and stackFab2-scFv-Fc formats) or antigen binding fragments thereof. Also provided herein are polynucleotide sequences encoding a chain and/or a CDR of a bispecific antibody of the disclosure; and vectors and cells comprising such polynucleotide sequences. Also provided herein are methods of treating cancer in a subject with a bispecific antibody of the disclosure.
    Type: Application
    Filed: November 7, 2022
    Publication date: May 18, 2023
    Inventors: Katrina Bykova, Matthew Faber, Matthew Bernett, Tian Zhang, Erik Pong, Kendra Avery, John Desjarlais
  • IL-18-FC FUSION PROTEINS
    Publication number: 20230146665
    Abstract: Provided herein are IL18-Fc fusion proteins that include an empty-Fc domain and an IL18 protein connected to another Fc domain. Also provided herein are additional are IL18-Fc fusion proteins such as IL18 x Fab-Fc fusion proteins that include a first monomer containing an IL18 protein connected to a first Fc domain, a second monomer containing a variable heavy chain connected to a second Fc domain, and a variable light chain, such that the variable heavy and light chains form an empty Fab. Various variant IL18 proteins with modifications to reduce heterogeneity and/or reduce affinity/potency and/or improve stability and/or improve production yield are also described.
    Type: Application
    Filed: July 26, 2022
    Publication date: May 11, 2023
    Inventors: Alex Nisthal, John Desjarlais, Gregory Moore, Sung-Hyung Lee
  • Heterodimeric proteins
    Patent number: 11634506
    Abstract: The invention provides novel heterodimeric proteins including heterodimeric antibodies.
    Type: Grant
    Filed: July 1, 2020
    Date of Patent: April 25, 2023
    Assignee: Xencor, Inc.
    Inventors: Gregory Moore, Matthew Bernett, Rumana Rashid, John Desjarlais